Non-viral vectors offer scalable, cost-effective alternatives for chimeric antigen receptor T cell therapy. In this Primer, Tretbar et al. highlight advances in the use of non-viral approaches, gene delivery methods, clinical outcomes and key considerations for translating these technologies into practice.
- U. Sandy Tretbar
- Joel G. Rurik
- Ulrich Blache